Kalaris Therapeutics (KLRS) Tops Q2 EPS by 2c

Kalaris Therapeutics (NASDAQ: KLRS) reported Q2 EPS of ($0.48), $0.02 better than the analyst estimate of ($0.50).

For earnings history and earnings-related data on Kalaris Therapeutics (KLRS) click here.

You May Also Be Interested In

• Westport Fuel Systems (WPRT) Misses Q2 EPS by 64c
• Alabama Power Co. 5.875% Sr. Notes Series 2007b (ALM) Tops Q2 EPS by 62c
• Pliant Therapeutics, Inc. (PLRX) Misses Q2 EPS by 2c